Solifenacin Succinate is named as an intervention in 2 current clinical trials in our China register. 2 are recruiting patients now. All registered phases are Not applicable. The sponsor with the most trials is Yin Ping (1). The most-studied condition is Overactive Bladder.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Efficacy of Electroacupuncture Versus Solifenacin Succinate for Female Overactive Bladder
NCT05798403 · ClinicalTrials.gov ↗ · Overactive Bladder
|
Not applicable | Recruiting | Yin Ping | China |
|
Vitamin D Treat-to-Target Strategy for Children With Overactive Bladder-Wet
NCT06201013 · ClinicalTrials.gov ↗ · Urinary Bladder, Overactive, Overactive Bladder, Urinary Incontinence, Urge
|
Not applicable | Recruiting | Children's Hospital of Chongqing Medical University | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
17 single-substance products containing Solifenacin Succinate on the HPRA medicines list.
No entry for Solifenacin Succinate in the EMA, FDA or German BfArM shortage lists we track.
| Lead sponsor | Trials |
|---|---|
| Yin Ping | 1 |
| Children's Hospital of Chongqing Medical University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 2 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name Solifenacin Succinate as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 2 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Yin Ping (1) and Children's Hospital of Chongqing Medical University (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 17 single-substance products containing Solifenacin Succinate, for example Solifenacin Clonmel 10 mg film-coated tablets (Clonmel Healthcare Ltd). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Solifenacin Succinate has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Solifenacin Succinate works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Solifenacin Succinate works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Solifenacin Succinate (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.